The numerous somatic mutations present in CC, including IDH1 mutations, FGFR2 or NTRK fusions, HER2 amplifications, and others, make it a particularly target-rich tumor that may be exploited by specific inhibitors [13,18]. This evidence concerns the gene ERBB2 and cholangiocarcinoma.